Amended Statement of Ownership (sc 13g/a)
February 13 2023 - 3:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
DENALI THERAPEUTICS INC.
(Name of Issuer)
Common Stock, Par Value $0.01 Per Share
(Title of Class of Securities)
24823R105
(CUSIP Number)
December 31, 2022
(Date of Event which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Douglas K. Bratton
United States
7,000,882 (1)
[ ]
5.2% (2)
IN
Crestline Investors, Inc.
Delaware
6,860,732 (1)
[ ]
5.1% (2)
CO
Crestline Management, L.P.
Delaware
6,860,732 (1)
[ ]
5.1% (2)
PN
Crestline SI (GP), L.P.
Delaware
6,860,732 (1)
[ ]
5.1% (2)
PN
AKDL, L.P.
Delaware
6,860,732
[ ]
5.1% (1)
PN
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024